Prostate Organoids Treated with Enzalutamide

Prostate organoid cultures were established from Pten^(i)pe−/− and Pten/Hif1a^(i)pe−/− mice at 3 months AGI and cultured as described (Karthaus et al, 2014 (link); Drost et al, 2016 (link); Abu El Maaty et al, 2022 (link)) and treated for 24 h with enzalutamide (MDV3100; Selleckchem; catalog No.S1250) at 25 and 50 μM, or vehicle (DMSO). C4‐2B (CRL‐3315), DU‐145 (HTB‐81), and PC‐3 (CRL‐1435) cells were obtained from ATCC and cultured in DMEM (4.5 g/l glucose, 10% FCS, 1% penicillin/streptomycin) at 37°C and 5% CO₂. Cell lines used were mycoplasma‐free but not recently authenticated. HIF1A silencing in PC‐3 cells was performed as described (Abu El Maaty et al, 2022 (link)).
C4‐2B cells were treated for 24 h with PX‐478 (Selleck Chemicals; catalog No.S7612) at 50 μM and/or with enzalutamide (MDV3100; Selleckchem; catalog No.S1250) at 10, 25 and 50 μM, or vehicle (DMSO). DU‐145 and PC‐3 cells were treated for 24 h with PX‐478 at 50 μM.